Asset profile
fludarabine/cyclophosphamide
Small molecule
Evidence outlook
No featureable registry evidence
The studies registered under this drug are withdrawn, terminated, post-marketing only, or belong to other products, so none can represent its own clinical progression.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
54 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fludarabine / Cyclophosphamide: this drug | Phase 1/2 | Small molecule | Chemotherapy | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | ||
| APG-2575(Lisaftoclax ) | Phase 3 | Small molecule | BCL-2 | ||
| AZD0120 | Phase 3 | Cell therapy | BCMA / CD19 | ||
| Blinatumomab | Phase 3 | Multispecific antibody | CD19 x CD3 | ||
| Descartes-08 | Phase 3 | Cell therapy | — | ||
| Divozilimab | Phase 3 | Monoclonal antibody | CD20 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| Frexalimab | Phase 3 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | ||
| Inebilizumab | Phase 3 | Monoclonal antibody | CD19 |
…and 39 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
February 2027 (1)
What to watch
April 2027 (1)
What to watch
December 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.